Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings
作者： Lisa Vermunt , , Graciela Muniz-Terrera , Lea ter Meulen , Colin Veal
DOI: 10.1186/S13195-019-0576-Y
关键词:
摘要: Recruitment is often a bottleneck in secondary prevention trials Alzheimer disease (AD). Furthermore, screen-failure rates these are typically high due to relatively low prevalence of AD pathology individuals without dementia, especially among cognitively unimpaired. Prescreening on risk factors may facilitate recruitment, but the efficiency will depend how link participation and pathology. We investigated whether common AD-related predict trial-ready cohort amyloid status across different prescreen settings. monitored prescreening four cohorts linked European Prevention Dementia (EPAD) Registry (n = 16,877; mean ± SD age = 64 ± 8 years). These included clinical cohort, research in-person online population-based cohort. Individuals were asked participate EPAD longitudinal study (EPAD-LCS), which serves as for trials. Amyloid positivity was measured cerebrospinal fluid part EPAD-LCS assessment. calculated numbers needed (NNPS) per participant that amyloid-positive. tested if age, sex, education level, APOE status, family history memory complaints or scores, previously collected cohorts, could status. A total 2595 participants contacted EPAD-LCS. Participation varied by setting between 3 59%. The NNPS 6.9 (clinical cohort), 7.5 (research 8.4 88.5 (population-based cohort). (n = 413 (16%)) associated with lower age (odds ratio (OR) age = 0.97 [0.95–0.99]), (OR = 1.64 [1.23–2.17]), male sex (OR = 1.56 [1.19–2.04]), positive dementia (OR = 1.66 [1.19–2.31]). Among EPAD-LCS, (33%) higher (OR = 1.06 [1.02–1.10]) ɛ4 allele carriership (OR = 2.99 [1.81–4.94]). results similar Numbers greatly Understanding informative recruitment strategy studies AD.
biomedcentral.com
ed.ac.uk
springer.com
vumc.nl
scilit.net参考文章(43)
Niels Schoenmaker, Willem A Van Gool, The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurology. ,vol. 3, pp. 627- 630 ,(2004) , 10.1016/S1474-4422(04)00884-1
Bruno Vellas, Paul S. Aisen, Cristina Sampaio, Maria Carrillo, Philip Scheltens, Bruno Scherrer, Giovanni B. Frisoni, Michael Weiner, Lon Schneider, Serge Gauthier, Christine C. Gispen-de Wied, Suzanne Hendrix, Howard Feldman, Jesse Cedarbaum, Ronald Petersen, Eric Siemers, Sandrine Andrieu, David Prvulovic, Jacques Touchon, Harald Hampel, Prevention trials in Alzheimer's disease: an EU-US task force report. Progress in Neurobiology. ,vol. 95, pp. 594- 600 ,(2011) , 10.1016/J.PNEUROBIO.2011.08.014
Robert C. Green, J. Scott Roberts, L. Adrienne Cupples, Norman R. Relkin, Peter J. Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A. Dessa Sadovnick, Kimberly A. Quaid, Clara Chen, Robert Cook-Deegan, Lindsay A. Farrer, Disclosure of APOE Genotype for Risk of Alzheimer's Disease The New England Journal of Medicine. ,vol. 361, pp. 245- 254 ,(2009) , 10.1056/NEJMOA0809578
Joshua D. Grill, James E. Galvin, Facilitating Alzheimer Disease Research Recruitment Alzheimer Disease & Associated Disorders. ,vol. 28, pp. 1- 8 ,(2014) , 10.1097/WAD.0000000000000016
Raisa B Gul, Parveen A Ali, Clinical trials: the challenge of recruitment and retention of participants. Journal of Clinical Nursing. ,vol. 19, pp. 227- 233 ,(2010) , 10.1111/J.1365-2702.2009.03041.X
Michael C. Donohue, Reisa A. Sperling, David P. Salmon, Dorene M. Rentz, Rema Raman, Ronald G. Thomas, Michael Weiner, Paul S. Aisen, The Preclinical Alzheimer Cognitive Composite JAMA Neurology. ,vol. 71, pp. 961- 970 ,(2014) , 10.1001/JAMANEUROL.2014.803
Blair H Smith, Archie Campbell, Pamela Linksted, Bridie Fitzpatrick, Cathy Jackson, Shona M Kerr, Ian J Deary, Donald J MacIntyre, Harry Campbell, Mark McGilchrist, Lynne J Hocking, Lucy Wisely, Ian Ford, Robert S Lindsay, Robin Morton, Colin N A Palmer, Anna F Dominiczak, David J Porteous, Andrew D Morris, Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness International Journal of Epidemiology. ,vol. 42, pp. 689- 700 ,(2013) , 10.1093/IJE/DYS084
Reisa A. Sperling, Paul S. Aisen, Laurel A. Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, Maria C. Carrillo, Bill Thies, Marcelle Morrison-Bogorad, Molly V. Wagster, Creighton H. Phelps, Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers & Dementia. ,vol. 7, pp. 280- 292 ,(2011) , 10.1016/J.JALZ.2011.03.003
Willemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans RJ Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea, Myriam Alexander, Ina S Almdahl, Steven E Arnold, Inês Baldeiras, Henryk Barthel, Bart NM Van Berckel, Kristen Bibeau, Kaj Blennow, David J Brooks, Mark A Van Buchem, Vincent Camus, Enrica Cavedo, Kewei Chen, Gael Chetelat, Ann D Cohen, Alexander Drzezga, Sebastiaan Engelborghs, Anne M Fagan, Tormod Fladby, Adam S Fleisher, Wiesje M Van Der Flier, Lisa Ford, Stefan Förster, Juan Fortea, Nadia Foskett, Kristian S Frederiksen, Yvonne Freund-Levi, Giovanni B Frisoni, Lutz Froelich, Tomasz Gabryelewicz, Kiran Dip Gill, Olymbia Gkatzima, Estrella Gómez-Tortosa, Mark Forrest Gordon, Timo Grimmer, Harald Hampel, Lucrezia Hausner, Sabine Hellwig, Sanna-Kaisa Herukka, Helmut Hildebrandt, Lianna Ishihara, Adrian Ivanoiu, William J Jagust, Peter Johannsen, Ramesh Kandimalla, Elisabeth Kapaki, Aleksandra Klimkowicz-Mrowiec, William E Klunk, Sebastian Köhler, Norman Koglin, Johannes Kornhuber, Milica G Kramberger, Koen Van Laere, Susan M Landau, Dong Young Lee, Mony De Leon, Viviana Lisetti, Alberto Lleó, Karine Madsen, Wolfgang Maier, Jan Marcusson, Niklas Mattsson, Alexandre De Mendonca, Olga Meulenbroek, Philipp T Meyer, Mark A Mintun, Vincent Mok, José Luis Molinuevo, Hanne M Møllergård, John C Morris, Barbara Mroczko, Stefan Van der Mussele, Duk L Na, Andrew Newberg, Agneta Nordberg, Arto Nordlund, Gerald P Novak, George P Paraskevas, Lucilla Parnetti, Gayan Perera, Oliver Peters, Julius Popp, Sudesh Prabhakar, Gil D Rabinovici, Inez HGB Ramakers, Lorena Rami, Catarina Resende De Oliveira, Juha O Rinne, Karen M Rodrigue, Eloy Rodríguez-Rodríguez, Catherine M Roe, Uros Rot, Christopher C Rowe, Eckart Rüther, Osama Sabri, Páscual Sanchez-Juan, Isabel Santana, Marie Sarazin, Johannes Schröder, Christin Schütte, Sang W Seo, Femke Soetewey, Hilkka Soininen, Luiza Spiru, Hanne Struyfs, Charlotte E Teunissen, Magda Tsolaki, Rik Vandenberghe, Marcel M Verbeek, Victor L Villemagne, Stephanie JB Vos, Linda JC van Waalwijk van Doorn, Gunhild Waldemar, Anders Wallin, Åsa K Wallin, Jens Wiltfang, David A Wolk, Marzena Zboch, Henrik Zetterberg, Amyloid Biomarker Study Group, None, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. ,vol. 313, pp. 1924- 1938 ,(2015) , 10.1001/JAMA.2015.4668
Owen Lancaster, Tim Beck, David Atlan, Morris Swertz, Dhiwagaran Thangavelu, Colin Veal, Raymond Dalgleish, Anthony J Brookes, Cafe Variome: General‐Purpose Software for Making Genotype–Phenotype Data Discoverable in Restricted or Open Access Contexts Human Mutation. ,vol. 36, pp. 957- 964 ,(2015) , 10.1002/HUMU.22841